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It has been accepted that receptor-mediated action of steroid hormones depends on 
both the receptor and the hormonal level.  The mechanism of transcription by steroid 
receptors is mediated by cofactors, which function as co-activators or co-repressors, 
while their non-genomic actions depend on receptors localized to the cell membrane. 
Recently, a number of environmental chemicals, which are now termed as endocrine 
disruptors, have been identified, and their unwanted effects on our lives have become 
serious problems all over the world.  Their adverse effects on endocrine systems in 
animals, mostly estrogenic or anti-estrogenic, have resulted in reproductive malfunction 
and developmental disorders.  Although aryl hydrocarbons exhibit estrogenic or anti- 
estrogenic activity through specific interaction with aryl hydrocarbon receptors, other 
chemicals seem to interact directly with estrogen receptors, α and β forms.  In this 
paper, we surveyed the most recent understanding of endocrine disruptors from the 
viewpoint of steroid receptor systems.  We suggest two potential mechanisms of action 
for endocrine disruptors.  Endocrine distruptors i) directly associate with steroid 
receptor systems and/or ii) associate with the growth factor or the neurotransmitter 
receptor systems, and then upregulate the mitogen-activated protein kinase signaling 
cascades, leading to the ligand-independent activation of steroid receptor systems. Using 
these steroid receptor-dependent mechanisms, it appears that endocrine disruptors 
disorder our endocrine systems.  We have proposed future suggestions to further 
understand endocrine disruptors from the viewpoint of steroid receptor systems. 
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Since the cloning of human glucocorticoid re- 
ceptor (Hollenberg et al., 1985), a number of 
nuclear receptors including steroid receptors 
have been identified (Mangelsdorf et al., 1995; 
Pfaff et al., 1997), and are now understood as 
transcription factors included in a nuclear re- 
ceptor superfamily (Freedman, 1999).  Recent- 
ly, estrogen receptors (ERs) have been shown to 
localize to the cell membrane, and their role in 
non-genomic actions have been demonstrated as 
well (Chen et al., 1999; Goetz et al., 1999). 
A number of environmental chemicals have 
been identified as endocrine disruptors, and their 
unwanted effects on our lives have become se- 
rious problems all over the world.  At present, 
their adverse effects on endocrine systems in 
animals, mostly estrogenic or anti-estrogenic, 
have resulted in reproductive malfunction and 
developmental disorders (Keith, 1997). Among 
endocrine disruptors identified so far, aryl 
hydrocarbons, dioxins, exhibit estrogenic or 
anti-estrogenic activity through specific inter- 
 
Abbreviations:  AhR, aryl hydrocarbon receptor; AR, androgen receptor; ARE, androgen responsive element; 
DES, diethylstilbeterol; EGF, epidermal growth factor; ER, estrogen receptor; ERE, estrogen responsive element; 
IGF, insulin-like growth factor; LBD, ligand binding domain; MAP mitogaen-activated protein; PR, progesterone 
receptor; PRE, progestin responsive element; PHA, polycyclic aromatic hydrocarbon 
* Present address: Sebelas Maret University, Surakarta 57126, Indonesia. Short-term student exchange promotion 








action with aryl hydrocarbon receptors (AhRs) 
(Osteen et al., 1997), while most other chemicals 
seem to interact directly with the ER system. 
In this paper, we give a brief overview of the 
recent understanding of the receptor-mediated 
actions of steroid hormones, and discuss the 




Recent  advances in the 
mechanism of action of steroids 
 
Nuclear receptors including steroid receptors 
have been understood as transcription factors, 
which mediate extracellular signals to the 
nucleus.  A carboxy-terminus region of steroid 
receptors, the ligand binding domain (LBD), spe- 
cifically interacts with cognate ligands, while 
the AF-2 domain recruits cofactors (Freedman, 
1999; also see Fig. 1). Once associated with es- 
trogens, ER is activated and recruits co-acti- 
vators such as those from the SRC-1 family and 
TIF2/GRIP1/NCoA2, to interact with the estro- 
gen responsive element (ERE) in responsive 
genes (McKenna and O’Malley, 2000; Freedman, 
1999).  When bound by an estrogen antagonist, 
ER recruits N-Cor and SMRT, co-repressors, 
and inhibits the transcription of estrogen respon- 
sive genes (McKenna and O’Malley, 2000). The 
concept of ER-dependent genomic actions has 
been accepted for other steroid receptor sys- 
tems.  Recently, growth factors, neurotrans- 
mitters and cyclins have been demonstrated to 
crosstalk with steroid receptor systems.  Epi- 
dermal growth factor (EGF), insulin-like 
growth factor (IGF) (Kato et al., 1995; Bunone 
et al., 1996) and dopamine (Mani et al., 1994) 
could activate ERα via the mitogen-activated 
protein (MAP) kinase pathway in a ligand- 
independent manner.  Cyclins directly interact 
with the unliganded ERα (Zwijsen et al., 1997). 
Progesterone receptor (PR) is also activated by 
dopamine through cAMP-dependent phospho- 
rylation, and associates with SRC-1e, a co- 
activator specific for PR, to interact with the pro- 
gestin responsive element (PRE) (Bai et al., 
1997; Brossens et al., 1999). On the other hand, 
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Fig. 1.  Mechanism of action of steroid hormones and endocrine disruptors.  A: Genomic  action.  Steroid 
hormones and endocrine disruptors diretly interact with intracellular steroid receptors.  This leads to the 
recruitment of cofactors for specific interaction with hormone responsive elements (HREs) in hormone re- 
sponsive genes.  On the other hand, endocrine disruptors interact with receptors for growth factors or neuro- 
transmitters to up-regulate mitogen-activated protein (MAP) kinase signaling.  This leads to the ligand- 
independent activation of steroid receptors for the association with cofactors as described above.  B: Non- 
genomic action.  Steroid hormones and endocrine disruptors associate with steroid receptors localized to the 
cell membrane.  This leads to the intracellular signaling pathways. 
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androgen receptor (AR) is activated by EGF, 
IGF and keratinocyte growth factor (KGF) 
through MAP kinase cascades, and binds to AP- 
1 and Ets, a co-activator specific for AR, to 
interact with the androgen responsive element 
(ARE) (Klocker et al., 1999; Culig et al., 1994). 
Along with the ligand-dependent and the 
ligand-independent genomic actions, non- 
genomic actions through the plasma membrane 
receptor have recently been demonstrated to 
play impotant roles in hormone responsive cells 
(Chen et al., 1999; Goetz et al., 1999).  In sum- 
mary, the steroid receptor system is not only a 
ligand-induced transcriptional enhancer, but 
also a mediator of common intracellular signal- 




and the mechanism of action 
 
Adverse effects of pharmaceuticals, industrial 
waste and environmental pollutants (now all 
acknowledged as endocrine disruptors) on our 
lives have become a serious problem in the 
world.  They disorder the endocrine system in 
animals directly or indirectly. It is obvious that 
they exert their effects in a receptor-dependent 
manner (Brouwer et al., 1998; Chia, 2000; 
Fenner-Crisp, 2000). 
Endocrine disruptors, which seemed to be 
closely related to ER systems, could be classi- 
fied into three groups:  estrogen mimics, anti- 
estrogens and anti-androgens (Sonnenschein 
and Soto, 1998; Gray et al., 1999a).  An initial 
target for these compounds is ER (Nishikawa et 
al., 1999).  Diethylstilbesterol (DES), a synthe- 
tic estrogen, behaves as an estrogen agonist 
(Hunter et al, 1999), and exposure to DES dur- 
ing the fetal period induces urogenital abnor- 
malities in males (Kuiper et al., 1998; Spearow 
et al., 1999), oligospermia (Krishnan et al., 
1993; Vom Saal et al., 1997), the increased 
incidence of undescended  testis (Kuiper et al., 
1998; Spearow et al., 1999) and hypertrophy of 
the prostate (Newbold, 1995).   Polycyclic 
aromatic hydrocarbons (PAHs) have an anti- 
estrogenic activity through AhR (Brouwer et 
al., 1998; Safe et al., 1998; Loaiza-Perez et al., 
1999), and decrease the estrogen level in the 
blood (Kohn et al., 1993; Alvarez et al., 2000), 
the ER level in the uterus (De Vito et al., 1992; 
Alvarez et al., 2000) and the number of matured 
follicles associated with the upregulation of the 
follicle-stimulating hormone (Alvarez et al., 
2000).  Endocrine disruptors, which seemed to 
be closely related to AR systems are Flutamide, 
vinclozolin, p,p'-DDE and procymidone, anti- 
androgens, which disorder prostate maturation 
(Gray et al., 1999b), and induce undescended 
testis (Gray et al., 1999b), hypospadia (Gray et 
al., 1999b; Ostby et al., 1999) and permanent 
nipples (Gray et al., 1999b; Ostby et al., 1999) 
during sex differentiation.  In adult animals, 
anti-androgens increase the serum levels of 
androgens, luteinizing hormone and estrogens 
(Ladics et al, 1998; Monosson et al., 1999), and 
induces spontaneous abortions, stillbirths, 
reproductive malfunction, neuroendocrine 
alteration, and disorder of immune systems 
(Goldman, 1997; Palanza et al, 1999; Alvarez et 
al., 2000). 
As demonstrated above, disorder of steroid 
receptor-mediated signaling systems by endo- 
crine disruptors leads to abnormal conditions in 
animal physiology.  It is important to note that 
some endocrine disruptors exhibit potential 
activities:  (i) to interact directly with endoge- 
nous steroids, (ii) to inhibit steroid receptor 
binding, non-competetively or (iii) to destroy 
receptor molecules or endogenous steroids 






Ligand-dependent and -independent signaling 
pathways by steroid receptors seem to provide 
insights into the understanding of the molecular 
basis of endocrine disruptors as summarized in 
Fig. 1.  We also summarized representative en- 
docrine disruptors identified so far in Table 1. 
Although a number of endocrine disruptors in 
our daily lives have been identified, little is 
known about their molecular basis.  It becomes 
an urgent subject to further understand the mo- 
lecular basis of the diverse actions of endocrine 
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Table 1. Representative endocrine disruptors 
 
Compound Use Receptor Reference 
DES Medicine ERα, ERβ 23, 30 
Bisphenol A 
 
ERα, ERβ 23, 37 
Nonylphenol 
 
ERα, ERβ 23, 37 
PAHs:HCB, HCH Pesticide AhR 25, 36 
o,p'-DDT 
 
ERα, ERβ 23 
p,p'-DDT 
 
ERα, ERβ 23 
Methoxychlor 
 
ERα, ERβ 23 
Endosulfan 
 
ERα, ERβ 23 
Chlordecone 
 
ERα, ERβ 23 
p,p'-DDE 
 
AR 14, 15, 32 
Linuron 
 
AR 14, 15, 32 
Vinclozolin 
 
AR 14, 15, 32 
Procymidone 
 
AR 14, 15, 32 
PCBs Industrial waste ERα, ERβ 15, 23 
Bisphenol A 
 
ERα, ERβ 23, 37 
4 Tert-octyphenol 
 
ERα, ERβ 23, 37 
4-Octyphenol 
 




AhR, aryl hydrocarbon receptor; AR, androgen receptor; DES, diethylstilbesterol; 
ER, estrogen receptor; HCB, hexachlorobenzene; HCH, hexachlorohexane; op'/pp'- 
DDT, dichlorodiphenyltrichloroethane; PAH, polycyclic aromatic hydrocarbon; 
PCB, polychlorinated hydroxybiphenyl; p,p'-DDE, 1,1-dichloro-2,2-bis(p-chloro- 





disruptors. Understanding endocrine disruptors 
from the viewpoint of steroid receptor-mediated 
signaling may allow us to overcome these glob- 
al problems.  In addition, it is obviously impor- 
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